Table 1.
Main characteristics of all studies included in the meta‐analysis
| Author | Year | Country (Racial descent) | Design | Methods | Case | Control | Case | Control | HWE (P) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/C | C/T | T/T | C/C | C/T | T/T | ||||||||
| Lung cancer | |||||||||||||
| Matullo( 42 ) | 2006 | Europe (Caucasian) | PB | TaqMan | 116 | 1094 | 44 | 56 | 16 | 383 | 544 | 167 | 0.249 |
| David‐Beabes( 34 ) | 2001 | USA (Caucasian) | PB | PCR‐RFLP | 178 | 453 | 76 | 78 | 24 | 175 | 210 | 68 | 0.701 |
| David‐Beabes( 34 ) | 2001 | USA (African) | PB | PCR‐RFLP | 153 | 234 | 90 | 54 | 9 | 136 | 88 | 10 | 0.365 |
| Misra( 43 ) | 2003 | Finland (Caucasian) | PB | TaqMan | 313 | 306 | 160 | 124 | 29 | 149 | 134 | 23 | 0.339 |
| López‐Cima( 44 ) | 2007 | Spain (Caucasian) | HB | PCR‐RFLP | 403 | 434 | 168 | 185 | 50 | 178 | 196 | 60 | 0.607 |
| Zienolddiny( 45 ) | 2006 | Norway (Caucasian) | PB | TaqMan | 220 | 250 | 114 | 90 | 16 | 115 | 111 | 24 | 0.709 |
| Improta( 46 ) | 2008 | Italy (Caucasian) | HB | PCR‐RFLP | 94 | 121 | 31 | 33 | 30 | 67 | 46 | 8 | 0.978 |
| Zhang( 47 ) | 2007 | China (Asian) | HB | TaqMan | 291 | 273 | 259 | 30 | 2 | 244 | 28 | 1 | 0.837 |
| Popanda( 48 ) | 2004 | Germany (Caucasian) | HB | PCR‐RFLP | 462 | 459 | 175 | 201 | 86 | 168 | 222 | 69 | 0.756 |
| Jacobsen( 49 ) | 2004 | Denmark (Caucasian) | Cohort | TaqMan | 246 | 269 | 95 | 123 | 28 | 113 | 113 | 43 | 0.105 |
| Xia( 50 ) | 2008 | China (Asian) | PB | TaqMan | 103 | 139 | 91 | 12 | 0 | 118 | 21 | 0 | 0.335 |
| Harms( 51 ) | 2004 | USA (Caucasian) | HB | PCR‐RFLP | 110 | 119 | 61 | 37 | 12 | 61 | 49 | 9 | 0.845 |
| Rky( 35 ) | 2006 | Sweden (Caucasian) | PB | TaqMan | 175 | 154 | 79 | 96 | 56 | 98 | NA | ||
| Wang( 36 ) | 2003 | USA (Mixed) | PB | PCR‐RFLP | 112 | 190 | 69 | 43 | 119 | 71 | NA | ||
| Bladder cancer | |||||||||||||
| Figueroa( 52 ) | 2007 | Spain (Caucasian) | HB | TaqMan | 1083 | 1010 | 392 | 524 | 167 | 398 | 468 | 144 | 0.733 |
| Stern( 53 ) | 2002 | USA (Caucasian) | HB | PCR‐RFLP | 233 | 209 | 90 | 110 | 33 | 94 | 91 | 24 | 0.781 |
| Broberg( 54 ) | 2005 | Sweden (Caucasian) | PB | MALDI‐TOF | 61 | 153 | 23 | 33 | 5 | 60 | 72 | 21 | 0.935 |
| Matullo( 42 ) | 2006 | Europe (Caucasian) | PB | TaqMan | 131 | 1094 | 46 | 61 | 17 | 383 | 544 | 167 | 0.248 |
| Matullo( 55 ) | 2005 | Italy (Caucasian) | HB | TaqMan/PCR‐RFLP | 317 | 317 | 99 | 155 | 63 | 117 | 148 | 52 | 0.652 |
| Sanyal( 56 ) | 2004 | Sweden (Caucasian) | PB | PCR‐RFLP | 311 | 246 | 131 | 129 | 51 | 107 | 109 | 30 | 0.782 |
| Andrew( 57 ) | 2008 | USA and Italy (Caucasian) | PB | TaqMan/PCR‐RFLP | 1046 | 1275 | 397 | 477 | 172 | 482 | 617 | 176 | 0.335 |
| Gangwar( 58 ) | 2009 | India (Asian) | HB | PCR‐RFLP | 212 | 250 | 135 | 68 | 9 | 159 | 80 | 11 | 0.816 |
| Fontana( 59 ) | 2008 | France (Caucasian) | HB | TaqMan | 51 | 45 | 8 | 28 | 15 | 4 | 23 | 18 | 0.376 |
HB, hospital‐based study; HWE, Hardy–Weinberg equilibrium; NA, not available; PB, population‐based study.